Titre : AlkB enzymes

AlkB enzymes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "AlkB enzymes : Questions médicales les plus fréquentes", "headline": "AlkB enzymes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les AlkB enzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "AlkB enzymes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dioxygenases", "url": "https://questionsmedicales.fr/mesh/D049308", "about": { "@type": "MedicalCondition", "name": "Dioxygenases", "code": { "@type": "MedicalCode", "code": "D049308", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "AlkB Homolog 1, histone H2a dioxygenase", "alternateName": "AlkB Homolog 1, Histone H2a Dioxygenase", "url": "https://questionsmedicales.fr/mesh/D000071498", "about": { "@type": "MedicalCondition", "name": "AlkB Homolog 1, histone H2a dioxygenase", "code": { "@type": "MedicalCode", "code": "D000071498", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.500" } } }, { "@type": "MedicalWebPage", "name": "AlkB Homolog 2, alpha-ketoglutarate-dependent dioxygenase", "alternateName": "AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase", "url": "https://questionsmedicales.fr/mesh/D000071499", "about": { "@type": "MedicalCondition", "name": "AlkB Homolog 2, alpha-ketoglutarate-dependent dioxygenase", "code": { "@type": "MedicalCode", "code": "D000071499", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.750" } } }, { "@type": "MedicalWebPage", "name": "AlkB Homolog 3, alpha-ketoglutarate-dependent dioxygenase", "alternateName": "AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase", "url": "https://questionsmedicales.fr/mesh/D000071500", "about": { "@type": "MedicalCondition", "name": "AlkB Homolog 3, alpha-ketoglutarate-dependent dioxygenase", "code": { "@type": "MedicalCode", "code": "D000071500", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.875" } } }, { "@type": "MedicalWebPage", "name": "AlkB Homolog 4, lysine demethylase", "alternateName": "AlkB Homolog 4, Lysine Demethylase", "url": "https://questionsmedicales.fr/mesh/D000071501", "about": { "@type": "MedicalCondition", "name": "AlkB Homolog 4, lysine demethylase", "code": { "@type": "MedicalCode", "code": "D000071501", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.937" } } }, { "@type": "MedicalWebPage", "name": "AlkB Homolog 5, RNA demethylase", "alternateName": "AlkB Homolog 5, RNA Demethylase", "url": "https://questionsmedicales.fr/mesh/D000071502", "about": { "@type": "MedicalCondition", "name": "AlkB Homolog 5, RNA demethylase", "code": { "@type": "MedicalCode", "code": "D000071502", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.968" } } }, { "@type": "MedicalWebPage", "name": "Alpha-ketoglutarate-dependent dioxygenase FTO", "alternateName": "Alpha-Ketoglutarate-Dependent Dioxygenase FTO", "url": "https://questionsmedicales.fr/mesh/D000071516", "about": { "@type": "MedicalCondition", "name": "Alpha-ketoglutarate-dependent dioxygenase FTO", "code": { "@type": "MedicalCode", "code": "D000071516", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.416.139.992" } } } ], "about": { "@type": "MedicalCondition", "name": "AlkB enzymes", "alternateName": "AlkB Enzymes", "code": { "@type": "MedicalCode", "code": "D000071496", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Shoshana C Williams", "url": "https://questionsmedicales.fr/author/Shoshana%20C%20Williams", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA." } }, { "@type": "Person", "name": "Rachel Narehood Austin", "url": "https://questionsmedicales.fr/author/Rachel%20Narehood%20Austin", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA. raustin@barnard.edu." } }, { "@type": "Person", "name": "Deyu Li", "url": "https://questionsmedicales.fr/author/Deyu%20Li", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA." } }, { "@type": "Person", "name": "Zhijie Xu", "url": "https://questionsmedicales.fr/author/Zhijie%20Xu", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China." } }, { "@type": "Person", "name": "Juliet Lee", "url": "https://questionsmedicales.fr/author/Juliet%20Lee", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Tocolytics for delaying preterm birth: a network meta-analysis (0924).", "datePublished": "2022-08-10", "url": "https://questionsmedicales.fr/article/35947046", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD014978.pub2" } }, { "@type": "ScholarlyArticle", "name": "Bayesian unanchored additive models for component network meta-analysis.", "datePublished": "2022-07-17", "url": "https://questionsmedicales.fr/article/35844085", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/sim.9520" } }, { "@type": "ScholarlyArticle", "name": "Pharmacological treatments in panic disorder in adults: a network meta-analysis.", "datePublished": "2023-11-28", "url": "https://questionsmedicales.fr/article/38014714", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD012729.pub3" } }, { "@type": "ScholarlyArticle", "name": "Thresholds for surfactant use in preterm neonates: a network meta-analysis.", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36600484", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/archdischild-2022-324184" } }, { "@type": "ScholarlyArticle", "name": "Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.", "datePublished": "2022-09-14", "url": "https://questionsmedicales.fr/article/36189211", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.1006860" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Oxygénases", "item": "https://questionsmedicales.fr/mesh/D010105" }, { "@type": "ListItem", "position": 6, "name": "Dioxygenases", "item": "https://questionsmedicales.fr/mesh/D049308" }, { "@type": "ListItem", "position": 7, "name": "AlkB enzymes", "item": "https://questionsmedicales.fr/mesh/D000071496" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : AlkB enzymes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur AlkB enzymes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur AlkB enzymes", "description": "Comment diagnostiquer une déficience en enzymes AlkB ?\nQuels tests sont utilisés pour évaluer l'activité des enzymes AlkB ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec les enzymes AlkB ?\nY a-t-il des marqueurs biologiques pour les enzymes AlkB ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur AlkB enzymes", "description": "Quels sont les symptômes d'une déficience en AlkB ?\nLes symptômes varient-ils selon le type d'AlkB ?\nComment les symptômes évoluent-ils avec l'âge ?\nY a-t-il des symptômes spécifiques liés au cancer ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur AlkB enzymes", "description": "Peut-on prévenir les déficiences en AlkB ?\nY a-t-il des recommandations diététiques ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation sur les risques est-elle importante ?\nLes vaccinations peuvent-elles jouer un rôle ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur AlkB enzymes", "description": "Quels traitements existent pour les déficiences en AlkB ?\nLa supplémentation en nutriments aide-t-elle ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques en cours ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur AlkB enzymes", "description": "Quelles complications peuvent survenir avec une déficience en AlkB ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications liées à des traitements ?\nLes complications varient-elles selon l'âge ?\nComment surveiller les complications ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur AlkB enzymes", "description": "Quels sont les principaux facteurs de risque pour les déficiences en AlkB ?\nL'environnement joue-t-il un rôle ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nY a-t-il des groupes à risque particulier ?", "url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Network+Meta-Analysis&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en enzymes AlkB ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des enzymes AlkB ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques et des analyses de métabolites peuvent être réalisés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, mais elles peuvent être utiles pour évaluer des tissus spécifiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec les enzymes AlkB ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la réparation de l'ADN, pouvant mener à des cancers ou des maladies génétiques." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques pour les enzymes AlkB ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains marqueurs peuvent indiquer l'activité ou la déficience des enzymes." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en AlkB ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des anomalies de croissance, des troubles neurologiques et un risque accru de cancer." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type d'AlkB ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, différents types d'AlkB peuvent entraîner des symptômes variés selon leur fonction." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver avec l'âge, surtout en cas d'exposition à des agents alkylants." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques liés au cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la fatigue, la perte de poids et des douleurs peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents selon la gravité." } }, { "@type": "Question", "name": "Peut-on prévenir les déficiences en AlkB ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais éviter les agents alkylants peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut aider à protéger l'ADN contre les dommages." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance précoce." } }, { "@type": "Question", "name": "L'éducation sur les risques est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sensibiliser aux risques liés aux agents alkylants est crucial pour la prévention." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles jouer un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les déficiences en AlkB." } }, { "@type": "Question", "name": "Quels traitements existent pour les déficiences en AlkB ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie génique et des médicaments ciblés pour améliorer la réparation de l'ADN." } }, { "@type": "Question", "name": "La supplémentation en nutriments aide-t-elle ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent que des antioxydants peuvent aider à réduire les dommages à l'ADN." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du type de déficience et des symptômes." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques en cours ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent de nouvelles thérapies pour les déficiences en AlkB." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie, mais certains traitements montrent des résultats prometteurs sur le long terme." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une déficience en AlkB ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent un risque accru de cancers et des troubles neurologiques graves." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Y a-t-il des complications liées à des traitements ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent entraîner des effets secondaires et des complications." } }, { "@type": "Question", "name": "Les complications varient-elles selon l'âge ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent être plus graves chez les personnes âgées ou immunodéprimées." } }, { "@type": "Question", "name": "Comment surveiller les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des examens réguliers et des tests de dépistage peuvent aider à surveiller les complications." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour les déficiences en AlkB ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des prédispositions génétiques et l'exposition à des agents alkylants." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des produits chimiques et à des radiations peut augmenter le risque." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers ou de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes comme le tabagisme et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque particulier ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes exposées à des agents chimiques au travail sont à risque accru." } } ] } ] }

Sources (10000 au total)

Tocolytics for delaying preterm birth: a network meta-analysis (0924).

Preterm birth is the leading cause of death in newborns and children. Tocolytic drugs aim to delay preterm birth by suppressing uterine contractions to allow time for administration of corticosteroids... To estimate relative effectiveness and safety profiles for different classes of tocolytic drugs for delaying preterm birth, and provide rankings of the available drugs.... We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov (21 April 2021) and reference lists of retrieved studies.... We included all randomised controlled trials assessing effectiveness or adverse effects of tocolytic drugs for delaying preterm birth. We excluded quasi- and non-randomised trials. We evaluated all st... At least two review authors independently assessed the trials for inclusion and risk of bias, and extracted data. We performed pairwise and network meta-analyses, to determine the relative effects and... This network meta-analysis includes 122 trials (13,697 women) involving six tocolytic classes, combinations of tocolytics, and placebo or no treatment. Most trials included women with threatened prete... Compared with placebo or no tocolytic treatment, all tocolytic drug classes that we assessed (betamimetics, calcium channel blockers, magnesium sulphate, oxytocin receptor antagonists, nitric oxide do...

Pharmacological treatments in panic disorder in adults: a network meta-analysis.

A panic attack is a discrete period of fear or anxiety that has a rapid onset and reaches a peak within 10 minutes. The main symptoms involve bodily systems, such as racing heart, chest pain, sweating... To compare, via network meta-analysis, individual drugs (antidepressants and benzodiazepines) or placebo in terms of efficacy and acceptability in the acute treatment of panic disorder, with or withou... We searched the Cochrane Common Mental Disorders Specialised Register, CENTRAL, CDSR, MEDLINE, Ovid Embase and PsycINFO to 26 May 2022.... We included randomised controlled trials (RCTs) of people aged 18 years or older of either sex and any ethnicity with clinically diagnosed panic disorder, with or without agoraphobia. We included tria... Two authors independently screened titles/abstracts and full texts, extracted data and assessed risk of bias. We analysed dichotomous data and continuous data as risk ratios (RRs), mean differences (M... Overall, we included 70 trials in this review. Sample sizes ranged between 5 and 445 participants in each arm, and the total sample size per study ranged from 10 to 1168. Thirty-five studies included ... In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings...

Thresholds for surfactant use in preterm neonates: a network meta-analysis.

To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of inspired oxyg... Systematic review and network meta-analysis using Bayesian analysis of randomised trials of prophylactic versus selective surfactant for RDS.... Cochrane Central Register of Controlled Trials, MEDLINE, Embase and Science Citation Index Expanded.... Randomised trials including infants under 32 weeks of gestational age.... Intratracheal surfactant, irrespective of type or dose.... Our primary outcome was neonatal mortality, compared between groups treated with selective surfactant therapy at different thresholds of FiO... Of 4643 identified references, 14 studies involving 5298 participants were included. We found no statistically significant differences between 30%, 40% and 50% FiO... Our results do not show a clear benefit of surfactant treatment at any threshold of FiO... CRD42020166620....

Common bile duct stones management: A network meta-analysis.

Timely management is critical for treating symptomatic common bile duct (CBD) stones; however, a single optimal management strategy has yet to be defined in the acute care setting. Consequently, this ... PubMed, SCOPUS, MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were methodically queried for articles from 2010 to 2021. The search terms were a combination of medical subject hea... A total of 16 studies (8,644 participants) addressing the LOS and 41 studies (19,756 participants) addressing postprocedural complications were included in the analysis. The one-stage approaches were ... This network meta-analysis suggests that both laparoscopic CBD exploration and intraoperative ERCP have equally good outcomes and provide a preferable single-anesthesia patient pathway with a shorter ... Systematic Review/Meta Analysis; Level III....

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.

In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS). While consensus supports these o... To compare through network meta-analysis the efficacy and safety of alemtuzumab, azathioprine, cladribine, cyclophosphamide, daclizumab, dimethylfumarate, diroximel fumarate, fingolimod, fludarabine, ... We searched CENTRAL, MEDLINE, and Embase up to August 2022, as well as ClinicalTrials.gov and the WHO ICTRP.... Randomised controlled trials (RCTs) that studied one or more treatments as monotherapy, compared to placebo or to another active agent, for use in adults with PMS.... Two review authors independently selected studies and extracted data. We performed data synthesis by pair-wise and network meta-analysis. We assessed the certainty of the body of evidence according to... We included 23 studies involving a total of 10,167 participants. The most frequent (39% of studies) reason for a rating of high risk of bias was sponsor role in study authorship and data management an... The number of people with PMS with relapses is probably slightly reduced with rituximab at two years, and interferon beta-1b at three years, compared to placebo. Both drugs are also probably associate...

Moist dressings in the treatment of pressure injuries: A network meta-analysis.

The aim of this network meta-analysis is to analyze the difference in therapeutic effects between moist dressings and traditional dressings in the treatment of pressure injury (PI), explore the healin... The incidence of pressure injury is high and the burden of disease is high, but there is no consensus on how to choose moist dressing treatment.... A systematic review with network meta-analysis was performed.... We searched the Chinese Biomedicine Literature Database and China National Knowledge Infrastructure, Wanfang Database, VIP database, PubMed, Web of Science, EMBASE.com, CENTRAL (Cochrane Central Regis... R studio software and Stata 16.0 software were used to compare different moist dressings and traditional dressings.... 41 RCTs of moist dressings in the treatment of PI were included. A total of seven kinds of moist dressings, Vaseline gauze and traditional gauze dressing were involved. All RCTs were at a medium to hi... The effect of moist dressings in treating PI is more advantageous than traditional dressings. However, in terms of direct cost and the number of dressings changes, more research is needed to improve t... This study is a network meta-analysis, which does not require the participation of patients and the public....